Navigation

Prostate cancer (metastatic, hormone relapsed, not treated with chemotherapy) - abiraterone acetate (with prednisolone) [ID503]

Abiraterone acetate for the treatment of metastatic hormone relapsed prostate cancer not previously treated with chemotherapy

Status: In development
Expected date of issue: TBC
Referral date: November 2011
Process: STA
Notes:

Scoped as part of Batch 20

Topic area:
  • Cancer
  • Urogenital
 

NICE project team

Executive Lead: Carole Longson
Technical Lead: Martyn Burke
Communications manager: Alice Law
Project manager:

Jeremy Powell

Top


 

Provisional schedule

Closing date for invited submissions / evidence submission: 16 January 2014
1st appraisal committee meeting: 15 April 2014
Top


 

Consultees and commentators

Consultees Commentators (no right to submit or appeal)

Manufacturers/sponsors

  • Janssen (abiraterone)

Patient/carer groups

  • Afiya Trust
  • Black Health Agency
  • Bob Champion Cancer Trust
  • Cancer Black Care
  • Cancer Equality
  • Counsel and Care
  • Equalities National Council
  • Everyman
  • Helen Rollason Cancer Charity
  • Independent Cancer Patients Voice
  • Macmillan Cancer Support
  • Maggie’s Centres
  • Marie Curie Cancer Care
  • Muslim Council of Britain
  • Muslim Health Network
  • Orchid
  • PCaSO – Prostate Cancer Network
  • Prostate Cancer Support Federation
  • Prostate Cancer UK
  • Prostate Help Association
  • South Asian Health Foundation
  • Specialised Healthcare Alliance
  • Tenovus

Professional groups

  • Association of Cancer Physicians
  • British Association of Urological Nurses
  • British Association of Urological Surgeons
  • British Geriatrics Society
  • British Institute of Radiology
  • British Prostate Group
  • British Psychosocial Oncology Society
  • British Uro-Oncology Group
  • Cancer Networks Pharmacists Forum
  • Cancer Research UK
  • Pelican Cancer Foundation
  • Royal College of General Practitioners
  • Royal College of Nursing
  • Royal College of Pathologists
  • Royal College of Physicians
  • Royal College of Radiologists
  • Royal Pharmaceutical Society
  • Royal Society of Medicine
  • Society and College of Radiographers
  • United Kingdom Clinical Pharmacy Association
  • United Kingdom Health Forum
  • United Kingdom Oncology Nursing Society
  • Urology Foundation

Others

  • Department of Health
  • NHS England
  • NHS Norwich CCG
  • NHS Wirral CCG
  • Welsh Government

General

  • Allied Health Professionals Federation
  • Board of Community Health Councils in Wales
  • British National Formulary
  • Care Quality Commission
  • Commissioning Support Appraisals Service
  • Department of Health, Social Services and Public Safety for Northern Ireland
  • Healthcare Improvement Scotland
  • Medicines and Healthcare Products Regulatory Agency
  • National Association of Primary Care
  • National Pharmacy Association
  • NHS Alliance
  • NHS Commercial Medicines Unit
  • NHS Confederation
  • Prostate Cymru, The Prostate Cancer Charity For Wales
  • Scottish Medicines Consortium

Possible comparator manufacturers

  • Actavis UK (docetaxel)
  • Hospira UK (docetaxel)
  • Medac UK (docetaxel)
  • Sandoz (docetaxel)
  • Sanofi-Aventis (docetaxel)
  • Teva UK (docetaxel)

Relevant research groups

  • Cochrane Prostatic Diseases and Urologic Cancers Group
  • Health Research Authority
  • Institute of Cancer Research
  • MRC Clinical Trials Unit
  • National Cancer Research Institute
  • National Cancer Research Network
  • National Institute of Health Research
  • Ovarian & Prostate Cancer Research Trust
  • Pro Cancer Research Fund
  • Research Institute of the Care of Older People

Evidence Review Group

  • Kleijnen Systematic Reviews
  • National Institute for Health Research Health Technology Assessment Programme

Associated guideline groups

  • National Collaborating Centre for Cancer

Associated public health groups

  • Public Health England
  • Public Health Wales NHS Trust

Top


 

Project history

Date

 

Update

 

03 January 2014 The appraisal was restarted in November 2013.

21 February 2013

 

This appraisal has been suspended because the manufacturer of abiraterone has informed us that they will not be able to make a submission for this appraisal at this time.

 

03 August 2012

 

Following on from advice received from the manufacturer, this appraisal has been rescheduled to align with latest regulatory expectations.  Therefore, we now anticipate that the appraisal will begin during early December 2012.

 

Top


 

Key documents

This page was last updated: 06 February 2014

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.